Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 3,815.7 | 3,316.7 | 2,988.1 | 2,660.1 | 2,660.1 | 2,231.9 | 1,847.9 | 1,607.3 |
| Revenue growth | 15.0% | 11.0% | 12.3% | 19.2% | | 20.8% | 15.0% | 15.9% |
| Cost of goods sold | 1,877.9 | 1,678.2 | 1,585.2 | 1,451.1 | 1,383.0 | 1,273.6 | 657.8 | 565.9 |
| Gross profit | 1,937.8 | 1,638.5 | 1,402.9 | 1,209.0 | 1,277.1 | 958.3 | 1,190.1 | 1,041.4 |
| Gross margin | 50.8% | 49.4% | 46.9% | 45.4% | 48.0% | 42.9% | 64.4% | 64.8% |
| Sales and marketing | 503.9 | 438.5 | 345.6 | 291.4 | 301.7 | 253.2 | 228.8 | 202.2 |
| Research and development | 706.3 | 560.4 | 492.6 | 434.0 | 491.8 | 355.8 | 287.8 | 270.2 |
| General and administrative | 345.8 | 323.8 | 362.1 | 334.0 | 334.0 | 282.4 | 221.2 | 219.7 |
| EBITA | 509.7 | 442.9 | 322.1 | 286.3 | 149.6 | 183.9 | 140.3 | 66.5 |
| EBITA margin | 13.4% | 13.4% | 10.8% | 10.8% | 5.6% | 8.2% | 7.6% | 4.1% |
| Amortization of intangibles | 127.9 | 127.1 | 119.5 | 136.7 | | 117.0 | 90.2 | 97.5 |
| EBIT | 381.8 | 315.8 | 202.6 | 149.6 | 149.6 | 66.9 | 50.1 | -31.0 |
| EBIT margin | 10.0% | 9.5% | 6.8% | 5.6% | 5.6% | 3.0% | 2.7% | -1.9% |
| Pre-tax income | 253.6 | -495.4 | 126.4 | 73.0 | 73.0 | 106.8 | -21.5 | -120.6 |
| Income taxes | 10.8 | -1.3 | -12.0 | -9.0 | -9.0 | -18.9 | 0.4 | -0.2 |
| Tax rate | 4.3% | 0.3% | | | | | | 0.2% |
| Earnings from continuing ops | 242.3 | -495.1 | 137.0 | 77.1 | 77.1 | 122.3 | -16.5 | -75.6 |
| Earnings from discontinued ops | | | | | | 14.1 | | |
| Net income | 242.3 | -495.1 | 137.0 | 77.1 | 77.1 | 136.4 | -16.5 | -75.6 |
| Net margin | 6.4% | -14.9% | 4.6% | 2.9% | 2.9% | 6.1% | -0.9% | -4.7% |
| |
| Diluted EPS | $1.42 | ($2.94) | $0.75 | $0.43 | $0.43 | $0.69 | ($0.21) | ($1.29) |
| Shares outstanding (diluted) | 171.1 | 168.6 | 181.7 | 181.4 | 181.4 | 177.1 | 79.8 | 58.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|